Zydus receives FDA’s ODD for Desidustat for the treatment of beta-thalassemia
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
These findings follow positive Phase 3 results presented earlier this year
Datamatics will automate the Medication Administration Record process by integrating its intelligent automation products, TruBot and TruCap+
Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
The platform is being introduced to expand access to treatments for people living with chronic conditions
Subscribe To Our Newsletter & Stay Updated